<DOC>
	<DOCNO>NCT01615653</DOCNO>
	<brief_summary>- Hypothesis : - Direct CGN enhance neurolytic drug delivery celiac ganglion increase efficacy neurolysis subsequent pain control survival patient pancreatic carcinoma . - Rationale : - Standard CPN lead inaccurate delivery injectate rapid dispersal thereby briefly remain contact neural structure limit degree neurolysis . Poor target delivery neurolytic agent may result diminished neurolysis decrease efficacy .</brief_summary>
	<brief_title>EUS Guided Celiac Neurolysis</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1 . Unresectable pancreatic carcinoma ( T4 M1 ) advance T3 disease 2 . Cytologic histologic confirmation pancreatic carcinoma 3 . Abdominal pain ( ≥ 3 NRS scale ) , ≥ 2 days/week , last ≥ 1 hour/ day , stable intensity ≥ 7 day 4 . EUS clinically indicate ( nonstudy purpose ) 1 . Uncorrectable coagulopathy : ( INR ) &gt; 1.5 and/or platelet &lt; 50,000 2 . Abdominal surgery within 1 month 3 . Prior celiac plexus ganglia neurolysis . 4 . Initiation modification chemotherapy radiotherapy within prior 7 day . 5 . Direct tumor infiltration celiac trunk and/or celiac ganglion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Pancreas cancer</keyword>
	<keyword>Pain</keyword>
	<keyword>Celiac Plexus</keyword>
	<keyword>Neurolysis</keyword>
</DOC>